Encycle Therapeutics: Encycle Therapeutics announces discovery collaboration with Pfizer Inc.

Toronto, Nov. 01, 2017 (GLOBE NEWSWIRE) - Encycle Therapeutics ("Encycle"), a Toronto-based drug discovery company built on a unique chemistry that enables the synthesis of a new type of constrained peptide called "nacellins," today announced a research collaboration with Pfizer Inc. ("Pfizer") (NYSE: PFE). Encycle and Pfizer will partner to optimize certain nacellins, which were previously identified by Pfizer during a screening of Encycle's proprietary nacellin library, that act on an undisclosed therapeutic target. Nacellins are a type of peptide macrocycle that can often exhibit higher permeability, solubility, and stability compared to conventional constrained peptides. The synthetic method [...]